Skip to main content
Evidence Based Longevity (EBL)Check what I take
Evidence Trace, complete trial record
In plain terms

In plain terms: Tongkat Ali (Eurycoma longifolia) shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.

Tongkat Ali (Eurycoma longifolia)

C Limited: small, mixed or unreplicated trials
Category Supplements
Evidence Small randomized trials and one meta-analysis, heterogeneous
Reviewed July 2026
PMIDs 33541567 · 36013514 · 34262417 · 33559971 · 37697053 · 26365449
The endpoint this grade is based on: Surrogate biomarker endpoint, Total testosterone in men with low testosterone, on small trials of standardized water extracts of the root: a 2022 meta-analysis of five randomized trials pooled a rise with very high heterogeneity, significant in men with low testosterone and not in healthy men. The largest placebo-controlled trial was funded and co-authored by the extract's maker. A hormone level is a surrogate, and no trial measured a health outcome.

The evidence as the record states it

Leitao et al. (Maturitas, 2021; PMID 33541567): 45 men with androgen deficiency of aging, four arms of placebo, 200 mg/day extract, concurrent training, or both for 6 months; the primary outcome was erectile function (IIEF-5) with the Aging Male Scale and total testosterone alongside, and the largest gains were in the extract-plus-training arm; the design does not isolate the extract's effect on testosterone. Chinnappan et al. (Food Nutr Res, 2021; PMID 34262417): 105 men aged 50 to 70 with testosterone below 300 ng/dL, 100 or 200 mg/day of a standardized water extract or placebo for 12 weeks; total testosterone rose, the primary endpoint; funded by the extract's maker, with two of its employees among the authors. Chan et al. (Andrologia, 2021; PMID 33559971): 32 healthy young men, 600 mg/day for 2 weeks; testosterone and free testosterone rose against placebo; university funded. Leisegang et al. (Medicina (Kaunas), 2022; PMID 36013514): meta-analysis of 5 randomized trials; pooled standardized mean difference 1.35 for total testosterone with I-squared about 87 percent, confirmed in the hypogonadal subgroup and not significant in healthy men. Morgado et al. (Int J Impot Res, 2024; PMID 37697053): systematic review of testosterone boosters rating this extract possibly effective in late-onset hypogonadism. Kotirum et al. (Complement Ther Med, 2015; PMID 26365449): meta-analysis of 2 randomized trials on erectile function, no overall difference. Grade C: small, inconsistent and largely maker-run evidence on a hormone level, positive in men with low testosterone and not in healthy men.

PMID 33541567 PMID 36013514 PMID 34262417 PMID 33559971 PMID 37697053 PMID 26365449

Evidence by specific use

Total testosterone in men with low testosterone
Grade C
Leisegang et al. (2022; PMID 36013514) pool 5 randomized trials: total testosterone higher (SMD 1.35) with I-squared about 87 percent, significant in men with low testosterone and not in healthy men. The largest placebo-controlled trial (Chinnappan et al., 2021; PMID 34262417; 105 men, 12 weeks) was funded and co-authored by the extract's maker. The record's original citation (Leitao et al., 2021; PMID 33541567) tested the extract with and without concurrent training and found the largest gains with both, so it does not isolate the extract. Chan et al. (2021; PMID 33559971) is a 2-week trial in healthy young men. Inconsistent, small, largely maker-run evidence on a hormone level: C. Morgado et al. (2024; PMID 37697053) rate it possibly effective in late-onset hypogonadism.
PMID 34262417 PMID 36013514 PMID 33541567 PMID 33559971 PMID 37697053
PMID 34262417 PMID 36013514 PMID 33541567 PMID 33559971 PMID 37697053

Why Grade C Route by_use and not Grade B

Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.

What would move this grade

A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.

How to track whether this is working Total and free testosterone at baseline and 12 weeks, the primary endpoints of the trials, with SHBG. The positive trials used standardized water extracts of the root, not unstandardized powders.